Hypertension

High blood pressure increases a patient's risk of heart attack, stroke and other diseases. Most people with hypertension have no symptoms. The Centers for Disease Control and Prevention (CDC) says nearly half of U.S. adults have hypertension, or high blood pressure, and only about 1 in 4 of those individuals has their hypertension under control. The World Health Organization (WHO) expects the epidemic of hypertension world-wide will exceed 1.56 billion people by 2025. Major efforts are underway to better control this primary risk factor through screenings, medication and invasive procedures such as renal denervation in severely uncontrolled patients.

Late-breaking cardiovascular drug trials took center stage at ACC.25
Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.
Early pregnancy blood pressure patterns tied to hypertension risk years later
Researchers show certain blood pressure patterns during the first 20 weeks of pregnancy were more likely to develop into hypertension later in life.
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension
The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH.
Boston Scientific enters renal denervation market with acquisition worth up to $540M
Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology.
Cardiovascular societies support Medicare coverage for renal denervation
CMS is expected to release a proposed national coverage determination decision memo by July.

Medtronic Announces Renal Denervation Pivotal Trial for the Treatment of Hypertension

DUBLIN — April 9, 2018 — Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension).

Hypertension

Late-breaking cardiovascular drug trials took center stage at ACC.25

Early pregnancy blood pressure patterns tied to hypertension risk years later

ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

Boston Scientific enters renal denervation market with acquisition worth up to $540M

Cardiovascular societies support Medicare coverage for renal denervation